

ASX ANNOUNCEMENT MARKET RELEASE

18 November 2022

RELEASE OF SHARES FROM VOLUNTARY ESCROW

Perth, Western Australia - Australian medical technology company, Artrya Limited (ASX: AYA, **Artrya or the Company**) creator of the AI-based solution, Artrya Salix, that supports physicians in the diagnosis of coronary artery disease, advises that in accordance with ASX Listing Rule 3.10A, a total of 25,634,357 fully paid ordinary shares (Shares) will be released from voluntary escrow on 26 November 2022.

Following the release of the Escrowed Shares, the remaining securities held in the Company that are subject to ASX imposed mandatory escrow arrangements are set out below.

ASX Mandatory Escrow

Number of Shares	Release Date
15,610,470	26 November 2023

Number of Options	Release Date
12,000,000	26 November 2023

This announcement was approved by the Artrya Managing Director and CEO.

For further information please contact:

Investor Enquiries:
John Barrington
Artrya Limited
+61 419 850 502
investors@artrya.com

Media Enquiries:
Brett McCarthy
Artrya Limited
+61 401 704 451
brett.mccarthy@artrya.com

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA).

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk. The company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.

For more information, see www.artrya.com